LN-145 + pembrolizumab

Drug identity checked against registry records

Also recorded as TIL, autologous tumor infiltrating lymphocytes; pembrolizumab (anti-PD-1 immunotherapy)

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495IOVAPhase 2Terminated2025-08-22Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.